Table 1

Schedule of assessments for the strategy to obtain warfarin or direct oral anticoagulant’s benefit by evaluating registry study

Study period
Visit	V1	V2	V3	V4
Timing (months, ±3)	0*	12	24	36
	Baseline assessment	Follow-up		Follow-up complete/early termination
Informed consent	●
Screening/eligibility	●
Basic information†	●
Annual examinations‡	●	●	●	●
Laboratory tests§	●	○	○	●
Physiological tests¶, brain MRI, GDS	●	○	○	●
Other examinations**	○	○	○	○
Brain scintigraphy (SPECT)	○	○	○	○
Apolipoprotein E	●
Clinical outcomes/endpoints		●	●	●

●: required, ○: optional.
*Information obtained within 3 months before informed consent can be used at enrolment.
†Basic information includes: (1) demographics and vital signs, (2) risk factors, (3) medical history, (4) medications, and (5) social factors and lifestyles.
‡Annual examinations include vital signs and comprehensive geriatric assessment consisting of a fundamental activities of daily living (ADL) scale (Barthel Index), instrumental ADL scale (Lawton and Brody), the Mini-Mental State Examination, Montreal Cognitive Assessment and Clinical Dementia Rating scale.
§Laboratory tests include blood count, blood biochemistry, urinalysis and biomarkers such as high-sensitive C reactive protein, interleukin 6, N-terminal pro B-type natriuretic peptide, cardiac troponin T, and alpha-2-macroglobulin.
¶Physiological tests include arterial stiffness assessment and echocardiography.
**Other examinations include carotid echography, neurophysiological, physical, and nutritional assessments.
GDS, Geriatric Depression Scale; SPECT, Single photon emission CT.